Ultra Clean Holdings, Inc. — Q2 2017 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2017. Unaudited results are compared with the quarter and six months ended June 24, 2016; balance-sheet figures are compared with December 30, 2016. Amounts below are in U.S. dollars unless stated otherwise.
Business context and performance
Ultra Clean designs, engineers, and manufactures tools, modules, and subsystems, primarily for semiconductor capital equipment manufacturers. Management attributed the sharp growth to higher shipment volumes and continued demand from major semiconductor customers. The company operates as one reportable segment.
| Metric | Q2 2017 | Q2 2016 | First half 2017 | First half 2016 |
|---|---|---|---|---|
| Sales | $228.3 million | $129.8 million | $432.9 million | $242.1 million |
| Gross profit | $43.4 million | $19.0 million | $80.9 million | $33.6 million |
| Gross margin | 19.0% | 14.7% | 18.7% | 13.9% |
| Operating income | $24.4 million | $3.7 million | $44.2 million | $3.0 million |
| Operating margin | 10.7% | 2.9% | 10.3% | 1.3% |
| Net income (loss) | $20.2 million | $0.7 million | $34.5 million | $(2.5) million |
| Diluted earnings (loss) per share | $0.59 | $0.02 | $1.01 | $(0.08) |
Financial position, cash flow, and liquidity
- Cash and cash equivalents were $59.5 million at June 30, up from $52.5 million at year-end 2016. Current assets were $307.9 million and current liabilities were $142.3 million.
- Six-month operating cash flow was $20.2 million, versus $3.6 million in the prior-year period. Receivables and inventory consumed $26.7 million and $35.2 million, respectively, partly offset by a $31.4 million increase in accounts payable.
- Investing cash outflow was $5.8 million and financing cash outflow was $7.5 million; cash increased by $7.0 million over the half-year. Management reported capital expenditures of $7.1 million, including amounts not yet paid.
- Total bank debt was approximately $60.8 million. U.S. term-loan and revolver balances were $16.2 million and $39.9 million; Miconex debt was $4.9 million. U.S. revolver availability was approximately $0.1 million, with an additional approximately $4.9 million available in the Czech Republic.
- The U.S. credit facility requires, among other terms, a minimum quarter-end cash balance of $35 million. The company reported compliance with its U.S. and Miconex covenants. Management said existing cash and operating cash flow should cover debt service and working capital needs for at least 12 months.
- Inventory purchase commitments totaled approximately $149.2 million, all classified as due within one year in the contractual-obligations table. The filing also reports $27.5 million of future minimum operating lease payments.
Material changes and management commentary
- Q2 sales increased 75.8% year over year; semiconductor revenue rose 79.6%. First-half sales increased 78.8%, including a reported $178.4 million increase in semiconductor-industry sales.
- Management attributed improved gross margins primarily to higher shipment volume, factory utilization, and labor efficiency. Operating expenses rose in dollars but declined as a share of sales, from 11.8% to 8.3% for Q2 and from 12.6% to 8.4% for the first half.
- Management expected Q3 2017 sales and gross profit to increase from Q2, citing continued semiconductor customer demand and expected higher revenue. No specific numerical forecast was provided.
- Interest and other expense increased to $1.1 million in Q2 and $2.1 million for the first half, primarily due to foreign-currency transaction losses.
- The fair value of the Miconex contingent earn-out liability increased from $0.3 million at year-end to $0.9 million at June 30; the $0.6 million increase was recorded as other expense.
- The effective tax rate was 13.3% for Q2 and 18.0% for the first half, compared with 75.1% and 330.2%, respectively, a year earlier. Management cited changes in the geographic mix of earnings and losses; full valuation allowances remained on specified U.S. and Singapore deferred tax assets.
- The company adopted share-based payment accounting guidance in Q1 2017, recognizing $1.7 million of previously excluded stock-option tax attributes with a corresponding valuation allowance.
Risks, contingencies, and other disclosures
- Customer concentration is substantial: Lam Research and Applied Materials together accounted for 82.8% of Q2 sales and 84.2% of first-half sales. The filing notes that customer orders generally lack minimum purchase commitments and can be delayed or cancelled.
- The business is exposed to semiconductor industry cyclicality, customer pricing leverage, supply constraints, production ramp and inventory risks, foreign-currency movements, and international operating risks. Management also highlighted the ongoing company-wide ERP implementation, planned across locations through fiscal 2019, as a risk to operations and financial reporting if unsuccessful.
- Approximately $43.3 million of cash was held by foreign subsidiaries and may be subject to U.S. tax if repatriated for U.S. operations; management intended to reinvest these funds outside the United States.
- Ordinary-course legal proceedings were disclosed; management did not expect them to have a material adverse effect. The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Verify the sustainability of the demand-driven sales and margin gains, and the Q3 outlook, given the company’s semiconductor-cycle exposure.
- Assess customer concentration, especially Lam Research’s 57.1% of Q2 sales and Applied Materials’ 25.7%, and the impact of any order reductions or pricing pressure.
- Monitor working-capital needs and inventory: inventory rose to $139.7 million, while purchase commitments were $149.2 million.
- Review debt-service flexibility, limited U.S. revolver availability, covenant headroom, and the availability and tax implications of offshore cash.
- Reconcile geographic sales disclosures: the geographic table reports Q2 U.S. sales of $129.3 million, while MD&A states $109.7 million; the filing text does not explain this discrepancy.